Market Overview

UPDATE: Jefferies Upgrades Sequenom to Buy on Reimbursement Coverage Outlook

Related SQNM
Sequenom To Explore The Clinical Utility Of A Novel Liquid Biopsy Assay In Melanoma Patients In Collaboration With University Of Colorado Denver
Sequenom Enters Clinical Collaboration With Seoul National University Hospital

Jefferies raised its rating on Sequenom (NASDAQ: SQNM) from Hold to Buy with a reiterated $7 price target.

Jefferies said, "We are upgrading shares of SQNM to Buy (from Hold) based on results from a proprietary survey we conducted of US commercial payors representing some 44 million lives, which indicated SQNM is experiencing meaningful traction obtaining reimbursement coverage for its T21 LDT test at average rates that we find more than acceptable. Our $7 price target (>90% upside) is unchanged."

Sequenom closed at $3.60 on Friday.

Latest Ratings for SQNM

Sep 2015JefferiesDowngradesBuyHold
Sep 2015William BlairDowngradesMarket Perform
Sep 2015Ladenburg ThalmannDowngradesSell

View More Analyst Ratings for SQNM
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (SQNM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters